Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications.
Activated protein C (APC), a natural anticoagulant, is formed from protein C by the action of thrombin bound to thrombomodulin on the endothelial cell surface. APC regulates the coagulation system by inactivating the activated form of factors V and VIII in the presence of protein S. Tumor necrosis factor-alpha (TNF-alpha) plays critical roles in the development of disseminated intravascular coagulation, acute respiratory distress syndrome and shock in sepsis by inducing endothelial cell damage through activation of neutrophils. APC reduces the pulmonary endothelial cell injury and hypotension in rats administered endotoxin (ET) by inhibiting TNF-alpha production through inhibition of its transcription. Furthermore, APC reduces the ischemia/reperfusion-induced renal injury and the stress-induced gastric mucosal injury in rats. Inhibition by APC of the endothelial cell damage inhibited the decrease in the endothelial production of prostacyclin in vivo. These therapeutic effects could not be attributed to its anticoagulant effects, but to inhibition of TNF-alpha production. APC inhibits ET-induced TNF-alpha production in vitro in human monocytes by inhibiting activation of NFkappaB and AP-1 by inhibiting degradation of IkappaB and mitogen-activated protein kinase pathways, respectively. Recombinant APC was reported to reduce the mortality of patients with severe sepsis. These observations strongly suggest that APC might be involved not only in regulation of the coagulation system, but in regulation of inflammatory responses by preventing endothelial cell injury. Furthermore, APC reduced the spinal cord injury induced by compression-trauma or ischemia/reperfusion by inhibiting TNF-alpha production in rats, suggesting that APC may be a potential therapeutic agent for spinal cord injury in which only limited therapeutic measures are currently available.
Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, School of Medicine, Honjo 1-1-1, Kumamoto 860-0811, Japan. whynot@kaiju.medic.kumamoto-u.ac.jp
Kenji
K
Okajima
D000818:Animals; D001777:Blood Coagulation / Q000502:physiology; D001779:Blood Coagulation Factors / Q000502:physiology; D002986:Clinical Trials as Topic; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000378:metabolism; D008168:Lung / Q000098:blood supply; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D011486:Protein C / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000502:physiology; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D018805:Sepsis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D012697:Serine Endopeptidases / Q000378:metabolism* / Q000627:therapeutic use; D013119:Spinal Cord Injuries / Q000188:drug therapy / Q000378:metabolism; D013276:Stomach Ulcer / Q000209:etiology / Q000378:metabolism; D013315:Stress, Psychological / Q000150:complications; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D001779:Blood Coagulation Factors; D011486:Protein C; D011956:Receptors, Cell Surface; D014409:Tumor Necrosis Factor-alpha; C091963:activated protein C receptor; D012697:Serine Endopeptidases